The cancer treatment Provenge, known as a "therapeutic vaccine," was approved by the Food and Drug Administration in April, 2010 as a novel way to attack prostate tumors. But this is more than the story of a new treatment. Host Bruce Japsen learns about the long path to FDA approval for this unique therapy that some see as a watershed development in oncology, from Dr. Mark Frohlich, senior vice president of clinical affairs and chief medical officer of Dendreon Corporation, the Seattle-based biotech company that manufactures Provenge.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
The Path to FDA Approval for a Therapeutic Cancer Vaccine
Restart
Resume
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
The cancer treatment Provenge, known as a "therapeutic vaccine," was approved by the Food and Drug Administration in April, 2010 as a novel way to attack prostate tumors. But this is more than the story of a new treatment. Host Bruce Japsen learns about the long path to FDA approval for this unique therapy that some see as a watershed development in oncology, from Dr. Mark Frohlich, senior vice president of clinical affairs and chief medical officer of Dendreon Corporation, the Seattle-based biotech company that manufactures Provenge.
Presenters
Facebook Comments